Last updated: February 13, 2026
Overview
IOBENGUANE I-131 (generic: I-131) is a radiopharmaceutical used primarily for thyroid cancer and hyperthyroidism treatments. Its market position depends on regulatory approvals, manufacturing capacity, treatment protocols, pricing strategies, and competing therapies. Its global market has exhibited growth constrained by production complexities, regulatory hurdles, and regional adoption rates.
Regulatory Status
- Approved in the U.S. by the Food and Drug Administration (FDA) in 2012.
- Approved in the European Union in 2013 via centralized procedures.
- Regulatory approvals in other regions are inconsistent, notably in emerging markets that face infrastructure limitations and regulatory delays.
- Licensing and manufacturing are controlled by a limited number of firms—most notably pharmaceutical giants like Nordion (a division of Sotera Health), Cardinal Health, and Amersham (a GE Healthcare division).
Manufacturing and Supply Chain
- Complex radiolabel production involves cyclotron irradiation of Tellurium-130.
- Short half-life (8 days) necessitates decentralized or regional manufacturing.
- Supply chain disruptions have historically impacted availability, especially during global demand surges or production issues.
Market Size and Growth Drivers
- The global radioiodine therapy market was valued at approximately USD 350 million in 2022.
- Expected to grow at a Compound Annual Growth Rate (CAGR) of around 4% from 2023-2030.
- Growth driven by increasing incidence of thyroid cancer, early detection, and expanding treatment guidelines that favor radioiodine therapy as standard care for differentiated thyroid cancer (DTC).
Regional Market Dynamics
- North America: Largest market, driven by high adoption rates, established healthcare infrastructure, and favorable reimbursement policies.
- Europe: Moderate growth; regulatory harmonization accelerates adoption.
- Asia-Pacific: Fastest growth due to rising thyroid cancer cases, expanding healthcare access, and government initiatives in nuclear medicine.
- Latin America and Africa: Limited penetration; growth possible with infrastructure improvements.
Competitive Landscape
- Key players: Nordion (Sotera), Cardinal Health, GE Healthcare.
- Market share fragmented; no dominant single provider.
- Patent exclusivities are limited due to generics and biosimilar competition.
- Entry barriers include regulatory approvals and high manufacturing complexity.
Pricing and Reimbursement
- Pricing varies by region; USD 750–1,200 per dose in North America.
- Reimbursement policies influence market access; in the U.S., Medicare and private insurers cover many treatments.
- Cost-effectiveness analyses favor radioiodine therapy over more invasive options, maintaining favorable reimbursement.
Financial Trajectory
- Revenue trends show steady but modest growth.
- Increased adoption in thyroid cancer management sustains demand.
- Potential growth catalysts include new clinical indications, improved manufacturing efficiencies, and regional market expansion.
- Patent and regulatory exclusivities are approaching expiration, risking increased generic competition.
- Investment in supply chain expansion could enhance market share and revenue stability.
Anticipated Market Challenges
- Supply constraints lead to shortages, especially in high-demand periods.
- Regulatory hurdles in emerging markets limit access.
- Competition from alternative therapies, such as targeted molecular treatments and immunotherapies for thyroid cancers.
- Safety concerns surrounding nuclear medicine procedures impose compliance costs.
Outlook
- The market for I-131 remains stable with moderate growth prospects.
- Technological innovations, such as improved delivery methods and companion diagnostics, could enhance market penetration.
- Commercial success hinges on manufacturing scalability and regulatory navigation across diverse geographies.
Key Takeaways
- IOBENGUANE I-131 is a niche but stable segment within nuclear medicine.
- Growth relies on rising thyroid cancer incidence, treatment guideline updates, and regional market expansion.
- Supply chain robustness and regulatory approvals are critical for sustained revenue.
- Competition from emerging therapies and generics presents future pricing pressures.
- Key regions for growth include North America, Europe, and Asia-Pacific.
FAQs
-
What are the main clinical indications for I-131?
Thyroid cancer, hyperthyroidism, and post-therapy ablation procedures.
-
How does I-131 pricing compare internationally?
Prices range USD 750–1,200 per dose in North America; lower in some European and Asian markets.
-
What factors influence manufacturing capacity?
Cyclotron irradiation of Tellurium-130, regional facilities, regulatory approvals, and supply chain logistics.
-
What regulatory challenges exist?
Differences in regional approval processes, infrastructure requirements, and safety regulations.
-
What are future growth opportunities?
Expansion into emerging markets, clinical trial approvals for new indications, and technology improvements.
References
[1] MarketWatch, "Radioiodine Therapy Market Size," 2023.
[2] GlobalData, "Thyroid Cancer Treatments Outlook," 2022.
[3] U.S. FDA, "Regulatory Approvals for I-131," 2012.
[4] European Medicines Agency, "Authorization of Radioiodine Therapy," 2013.
[5] World Nuclear Association, "Nuclear Medicine Industry," 2023.
